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Abstract
Introduction To establish a prognostic model for predicting 14-
day mortality in ICU patients with severe sepsis overall and
according to place of infection acquisition and to sepsis episode
number.
Methods In this prospective multicentre observational study on
a multicentre database (OUTCOMEREA) including data from
12 ICUs, 2268 patients with 2737 episodes of severe sepsis
were randomly divided into a training cohort (n = 1458) and a
validation cohort (n = 810). Up to four consecutive severe
sepsis episodes per patient occurring within the first 28 ICU
days were included. We developed a prognostic model for
predicting death within 14 days after each episode, based on
patient data available at sepsis onset.
Results Independent predictors of death were logistic organ
dysfunction (odds ratio (OR), 1.22 per point, P < 10-4), septic
shock (OR, 1.40; P = 0.01), rank of severe sepsis episode (1
reference, 2: OR, 1.26; P = 0.10 ≥ 3: OR, 2.64; P < 10-3),
multiple sources of infection (OR; 1.45, P = 0.03), simplified
acute physiology score II (OR, 1.02 per point; P  < 10-4),
McCabe score ([greater than or equal to]2) (OR, 1.96; P < 10-
4), and number of chronic co-morbidities (1: OR, 1.75; P < 10-
3, ≥ 2: OR, 2.24, P < 10-3). Validity of the model was good in
whole cohorts (AUC-ROC, 0.76; 95%CI, 0.74 to 0.79; and HL
Chi-square: 15.3 (P = 0.06) for all episodes pooled).
Conclusions In ICU patients, a prognostic model based on a
few easily obtained variables is effective in predicting death
within 14 days after the first to fourth episode of severe sepsis
complicating community-, hospital-, or ICU-acquired infection.
Introduction
Severe sepsis remains a leading cause of death in industrial-
ised countries, and the number of deaths caused by sepsis is
increasing despite improved survival rates [1,2]. Apart from
measures directed to the infectious cause (antibiotics and sur-
gery), the treatment remains chiefly supportive despite many
randomised controlled trials [3,4]. Sepsis is a syndrome, not a
disease; and many factors explain the variability of outcomes,
APACHE II: Acute Physiologic and Chronic Health Evaluation II; AUC: area under the curve; CI: Confidence Intervals; DNR: do not resuscitate; FiO2: 
fraction of inspired oxygen; HL: Hosmer-Lemeshow chi-squared test; ICU: intensive care unit; LOD: Logistic Organ Dysfunction; MPM II0: Mortality 
Probability models II0; OR: odds ratio; PaO2: partial pressure of arterial oxygen; PCO2: partial pressure of carbon dioxide; ROC: receiver-operating 
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such as differences in infection sites, causative pathogens,
and time and location of infection onset (community, hospital
or intensive care unit (ICU)) [1]. This heterogeneity explains
that no reliable measures of disease activity have been identi-
fied. Attempts to select uniform populations often used ill-
defined non-inclusion criteria such as moribund status.
Despite the current tendency to focus on mortality rates after
one year or longer, which are highly relevant to cost-effective-
ness issues, short-term mortality may be a more appropriate
outcome for determining whether new treatments correct the
acute effects of severe sepsis. This is because many patients
who recover from severe sepsis die later from pre-existing
chronic illnesses. Moreover, outcomes and risk factors of
patients with severe sepsis vary considerably with the number
of episodes and with the time and place (community, hospital
or ICU) of acquisition.
The objective of this study was to design a prognostic model
for predicting death within 14 days of severe sepsis onset at
any time during the first 28 days of the ICU stay. The model
was to be based on variables collected at admission and on
the day the sepsis episode was diagnosed. Up to four sepsis
episodes per patient were included. We evaluated the per-
formance of our model separately in subgroups defined based
on the place of infection acquisition. We compared our model
with other, widely used scores. Our model may prove useful
for designing future studies.
Methods and materials
Data source
We conducted a prospective observational study using data
entered into a multicentre database (OUTCOMEREA®) from
November 1996 to April 2007. The database, with input from
12 French ICUs, contains data on admission features and
diagnosis, daily disease severity, iatrogenic events, nosoco-
mial infections and vital status. Data for a random sample of at
least 50 patients older than 16 years and having ICU stays
longer than 24 hours were consecutively entered into the data-
base each year. Each participating ICU chose to perform ran-
dom sampling by taking either consecutive admissions to
selected ICU beds throughout the year or consecutive admis-
sions to all ICU beds over a single month. The contact physi-
cians for the database in the participating ICUs, who are listed
in the appendix, are accredited according to French law [5].
Ethical issues
According to French law, this study did not require patient
consent, because it involved research on a database. The
study was approved by the institutional review board of the
Centres d'Investigation Rhône-Alpes-Auvergne.
Data collection
Data were collected daily by senior physicians in the partici-
pating ICUs. For each patient, the data were entered into an
electronic case-report form using VIGIREA® and RHEA® data-
capture software (OUTCOMEREA™, Rosny-sous-Bois,
France), and all case-report forms were then entered into the
OUTCOMEREA® data warehouse. All codes and definitions
were established prior to study initiation. The following infor-
mation was recorded for each patient: age, sex, admission cat-
egory (medical, scheduled surgery or unscheduled surgery),
origin (home, ward or emergency room) and McCabe score
[6]. Based on previously reported reproducibility data, the
McCabe score was transformed into a dummy variable, that is,
'death expected within five years, yes or no' [7]. Severity of ill-
ness was evaluated on the first ICU day using the Simplified
Acute Physiology Score (SAPS II) [8], Logistic Organ Dys-
function (LOD) score [9], Sequential Organ Failure Assess-
ment (SOFA) score [10], Mortality Probability models II0 score
(MPM0 II score) [11,12], and Acute Physiologic and Chronic
Health Evaluation (APACHE) II score [13]. Knaus scale defini-
tions were used to record pre-existing chronic organ failures
including respiratory, cardiac, hepatic, renal and immune sys-
tem failures [13]. Patients were followed until the end of the
hospital stay in order to record the vital status 14 days after
sepsis onset. For the model, we computed SAPS II and LOD
scores based on the data immediately available on admission
or on the day (up to 24 hours) before the diagnosis of each
episode of sepsis.
Quality of the database
The data-capture software automatically conducted multiple
checks for internal consistency of most of the variables at entry
in the database. Queries generated by these checks were
resolved with the source ICU before incorporation of the new
data into the database. At each participating ICU, data quality
was controlled by having a senior physician from another par-
ticipating ICU check a 2% random sample of the study data.
Study population
Because diagnostic coding has been found to be unreliable
[14], we used parameters collected by our data-capture soft-
ware to select patients with severe sepsis, defined as systemic
inflammatory response syndrome (SIRS) combined with an
infectious episode and dysfunction of at least one organ,
occurring at or within 28 days after admission to the ICU. We
excluded patients with treatment-limitation decisions taken
before or on the day of the diagnosis of severe sepsis. At least
two of the following criteria were required for the diagnosis of
SIRS: core temperature of 38°C or above or 36°C or less,
heart rate of 90 beats/min or above, respiratory rate of 20
breaths/min or above, partial pressure of carbon dioxide
(PCO2) of 32 mmHg or less or use of mechanical ventilation,
and peripheral leukocyte count of 12,000/mm3 or above or
4000/mm3 or less. Organ dysfunction was defined as follows:
cardiovascular system failure was a need for vasoactive and/
or inotropic drugs, and/or systolic blood pressure less than 90
mmHg, and/or a drop in systolic blood pressure by more than
40 mmHg from baseline; renal dysfunction was urinary outputAvailable online http://ccforum.com/content/13/3/R72
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of 700 ml/day or less in a patient not previously undergoing
haemodialysis for chronic renal failure; respiratory dysfunction
was a partial pressure of arterial oxygen (PaO2) of less 70
mmHg or mechanical ventilation or a PaO2/fraction of inspired
oxygen (FiO2) ratio of 250 or less (or 200 or less in patients
with pneumonia); thrombocytopenia was a platelet count of
less than 80,000/mm3, and elevated plasma lactate was a lac-
tate level of 3 mmol/L or above. Severe sepsis was defined as
sepsis associated with at least one organ dysfunction as
described above, and septic shock was defined as sepsis-
induced hypotension persisting despite adequate fluid resus-
citation together with organ dysfunction. Thus, patients receiv-
ing inotropic or vasoactive agents who had organ dysfunction
but who were no longer hypotensive were classified as having
septic shock [15]. Lengths of ICU and hospital stays were
computed starting at ICU admission.
The presence or absence of infection was documented
according to the standard definitions developed by the Cent-
ers for Disease Control [16]. In addition, quantitative cultures
of specimens obtained by bronchoalveolar lavage, protected
specimen brush, protected plugged catheter or tracheal aspi-
ration were required to diagnose ventilator-associated pneu-
monia [17]. Community-acquired infection was defined as
infection manifesting before or within 48 hours after hospital
admission. Hospital-acquired infection was infection manifest-
ing at least 48 hours after hospital admission but before ICU
admission. ICU-acquired infection was diagnosed at least 48
hours after ICU admission. Infection sites were categorised as
follows: pneumonia, peritonitis, urinary tract infection, exacer-
bation of chronic obstructive pulmonary disease, primary
bacteraemia (excluding untreated Staphylococcus epider-
midis bacteraemia), miscellaneous sites (mediastinitis, prosta-
titis, osteomyelitis and others), and multiple sites. Early
effective antibiotic therapy was defined as effectiveness on the
causative agent of at least one of the empirically selected anti-
biotics on the day of the diagnosis of an episode of severe
sepsis. Relapse/recurrence was defined as a new episode of
severe sepsis with the same microorganism and the same
infected organ. New episodes of severe sepsis involving differ-
ent microorganisms or different organs from the previous epi-
sode were classified as separate episodes [18].
Outcome variable of interest
The outcome variable of interest was death within 14 days
after the diagnosis of an episode of severe sepsis (up to four)
acquired in the community, hospital or ICU.
We then compared the accuracy of these models with the
main ones usual used (SAPS II and APACHE II scores and
MPM II0).
Statistical analysis
Our main objective was to develop a patient-based prognostic
model that predicted death within 14 days after the diagnosis
of the first, second, third or fourth episode of severe sepsis
present within 28 days after ICU admission. We randomly allo-
cated two-thirds of the study patients to the training cohort
and the remaining one-third to the validation cohort. Up to four
episodes of severe sepsis per patient were included, so we
conducted a cluster analysis, in which each cluster was com-
posed of one patient with one to four sepsis episodes.
Results were expressed as numbers (percentages) for cate-
gorical variables and as medians (quartiles) for continuous var-
iables. Qualitative variables were compared using the chi-
squares or Fisher's exact test and continuous variables using
the Wilcoxon or Kruskal-Wallis test. A correlation exists
between the 14-day outcomes of two consecutive episodes of
severe sepsis occurring in the same patient. Consequently,
the relation between early death and the study variables was
evaluated using generalised estimating equations [19], which
are well suited to the analysis of correlated data. We used a
logit link function, because the distribution of the outcome var-
iable (14-day mortality) was binary. Correlations between mul-
tiple episodes of severe sepsis occurring in the same patient
were estimated using Pearson residuals and parameters,
according to the maximum likelihood method. We assumed an
exchangeable-structure correlation matrix for the data within
each cluster. The number of the sepsis episode and the time
from admission to the severe sepsis episode were introduced
successively into the global model, and the final model that
minimised the Akaike information criterion was retained.
Variables associated with early death at the 0.2 level by univar-
iate analysis were introduced in the multivariate model and
subsequently selected in order to improve model deviance.
The assumption that quantitative variables were linear in the
logit was checked using cubic polynomials and graphical
methods. In the absence of log-linearity, continuous variables
were transformed into qualitative variables according to the
slope of the cubic polynomial functions and to the distribution
of the variables. A pooled test of clinically relevant two-way
interactions was performed on the final model and correlations
between selected variables were verified. We checked for
potential co-linearity of the variables included in the final
model. R values of less than 0.2 were considered acceptable.
Our primary assessment of model performance was good-
ness-of-fit as evaluated by the Hosmer-Lemeshow statistic
and by calibration curves. Lower Hosmer-Lemeshow values
and higher P  values (> 0.05) indicate better fit. We also
assessed discrimination (i.e., the ability of the model to sepa-
rate survivors and non-survivors) using the area under the
curve (AUC) of the receiver-operating characteristics (ROC)
curve. AUC values greater than 0.80 indicate good discrimina-
tion.
The quality of our model was tested separately in community-
acquired, hospital-acquired and ICU-acquired sepsis. Then,Critical Care    Vol 13 No 3    Adrie et al.
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the final model was evaluated in the validation cohort and com-
pared with other models (SAPS II scores, APACHE II scores
and MPM II0 score) using the method of Hanley and McNeil to
compare AUC-ROC values [19]. Analyses were computed
using the SAS 9.1.3 package (SAS Institute, Cary, NC, USA),
R and Medcalc 5.00 (Medcalc, Ghent, Belgium).
Results
Among the 7719 patients in the OUTCOMEREA® base, 2268
experienced 2737 episodes of severe sepsis, including 674
patients who had 793 episodes of septic shock. Of the 2268
patients, 1458 patients with 1716 episodes of severe sepsis
were included in the training cohort and 810 patients with
1021 episodes of severe sepsis were included in the valida-
tion cohort (Figure 1), using a 2:1 randomisation procedure.
Characteristics at ICU admission and on the day of severe
sepsis onset in 14-day survivors and non-survivors are shown
in Tables 1 and 2, respectively. Factors that were significantly
associated with early death included worse SAPS II and LOD
scores at ICU admission, septic shock (e.g. requiring either
inotropic therapy or vasoactive agent support), multiple organ
failure (which showed the strongest association) and co-mor-
bidities (immunodeficiency, chronic heart failure, chronic
hepatic failure, acute respiratory failure and acute heart fail-
ure). On the day of the diagnosis of severe sepsis (Table 2),
factors significantly associated with early death included the
use of invasive procedures and a need for vasoactive agents
and/or inotropic support. Escherichia coli, Pseudomonas spe-
cies, methicillin-resistant Staphylococcus aureus, Candida
species, bacteraemia and multiple sources of infection were
also associated with early death in the univariate analysis.
We determined the best generalised linear model, that is, the
model comprising variables that were both readily available
and independently associated with early death (Table 3).
Among variables collected on the day of diagnosis of severe
sepsis, four were associated with an increased risk of early
death: worse LOD score, vasoactive and/or inotropic therapy
(e.g., septic shock), second episode of severe sepsis com-
pared with the first, and third or fourth episode of sepsis com-
pared with the first. Among infection characteristics entered
into the model, only multiple sources of infection significantly
Figure 1
Flow diagram of the 2268 patients with severe sepsis who formed the basis for the study and were identified among the 7719 patients included in  the Outcomerea® Database Flow diagram of the 2268 patients with severe sepsis who formed the basis for the study and were identified among the 7719 patients included in 
the Outcomerea® Database. Data are expressed as counts (number of episodes of severe sepsis (SS)) or percentages. Mortality is defined as death 
within 14 days after the diagnosis of severe sepsis. community-acquired infection = infection manifesting before or within 48 hours after hospital 
admission; hospital-acquired infection = infection manifesting at least 48 hours after hospital admission but before ICU admission; ICU = intensive 
care unit; ICU-acquired infection = infection manifesting at least 48 hours after ICU admission; N = number of patients (number of episode); Sepsis 
= SIRS with infection; SIRS = systemic inflammatory response syndrome. ✞ Mortality (percentage %).Available online http://ccforum.com/content/13/3/R72
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Table 1
Baseline characteristics at ICU admission of 1458 patients with severe sepsis
Variables at ICU admission Patients alive 14 days after severe 
sepsis (n = 1177)
Patients who died within 14 days 
after severe sepsis (n = 281)
P value Chi-squared test
Male gender 725 (61.6) 188 (66.9) 0.10
Age 66 (52 to 76) 69 (56 to 77) < 10-2
Transfer from ward 600 (51) 145 (51.6) 0.85
SAPS II 41 (31 to 53) 59 (44 to 5) < 10-4
LOD 4 (2 to 6) 7 (5 to 10) < 10-4
SOFA 6 (4 to 8) 9 (7 to 12) < 10-4
APACHE II 18 (14 to 22) 24 (20 to 29) < 10-4
Admission category (4 missing)
Medical 845 (71.8) 207 (73.7) 0.53
Emergency surgery 230 (19.5) 52 (18.5) 0.69
Scheduled surgery 98 (8.3) 22 (7.8) 0.79
McCabe score (4 missing) (1 missing) < 10-4
1 694 (59) 99 (35.2)
2 397 (33.7) 134 (47.7)
3 82 (7) 47 (16.7)
Main symptom at admission
Multiple organ failure 39 (3.3) 29 (10.3) < 10-2
Shock 367 (31.2) 105 (37.4) 0.05
Acute respiratory failure 384 (32.6) 73 (26) 0.03
Exacerbation of COPD 61 (5.2) 12 (4.3) 0.53
Acute renal failure 50 (4.2) 10 (3.6) 0.60
Coma 140 (11.9) 39 (13.9) 0.36
Trauma 12 (1) 1 (0.4) 0.29
Continuous monitoring 97 (8.2) 7 (2.5) < 10-2
Scheduled surgery 27 (2.3) 5 (1.8) 0.60
History of immunodeficiency
Haematological malignancy 78 (6.6) 29 (10.3) 0.03
Metastatic cancer 59 (5) 25 (8.9) 0.01
AIDS 41 (3.5) 16 (5.7) 0.09
Chemotherapy 90 (7.6) 32 (11.4) 0.04
Steroid therapy 68 (5.8) 28 (10) 0.01
Neutropenia 42 (3.6) 13 (4.6) 0.40
Co-morbidities 
(Knaus definitions)
Chronic pulmonary failure 198 (16.8) 57 (20.3) 0.17
Immunodeficiency 187 (15.9) 67 (23.8) < 10-2
Chronic heart failure 142 (12.1) 48 (17.1) 0.02
Chronic hepatic failure 52 (4.4) 35 (12.5) < 10-2Critical Care    Vol 13 No 3    Adrie et al.
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increased the risk of early death. Interestingly, the nature of the
causative microorganism was not an independent predictor of
death. Among variables collected at ICU admission, the follow-
ing significantly predicted death within 14 days of a sepsis epi-
sode: worse SAPS II score, presence of a fatal underlying
disease yielding a McCabe score of two or three, presence of
one chronic illness, and presence of two or more chronic ill-
nesses. Corticosteroid therapy did not predict early death,
even when interactions with septic shock were tested (odds
ratio (OR) = 0.99, 95% CI 0.66 to 1.49, P = 0.96), and there-
fore was not included in our model. Absence of early effective
antibiotic therapy was associated with death (OR = 0.69,
95% CI 0.53 to 0.91, P = 0.01) but was not introduced in the
model because this information was not available on the day of
severe sepsis.
Despite the risk of co-linearity, we considered that LOD on the
first day of sepsis and SAPS II at admission could be used in
the same model. First, when sepsis was acquired in the ICU,
the variables shared by these two scores were not recorded at
the same time. Second, using two scores in the same model
decreases the loss of information caused by differences in cut-
offs. There was no significant co-linearity between our varia-
bles (All R values < 0.2).
We tested our model in the training cohort in each of the three
categories of patients defined by the site of infection acquisi-
tion (community, hospital or ICU; Figure 2). In the overall train-
ing cohort, the final model exhibited good calibration (Hosmer-
Lemeshow (HL) chi-squared, 8.6; P > 0.38) and good discrim-
ination (AUC-ROC curve, 0.82). When we confined the anal-
ysis to the 573 episodes of community-acquired severe
sepsis, the final model showed good calibration (HL chi-
squared, 8.0; P > 0.43) and discrimination (AUC-ROC curve,
0.87). Validity was satisfactory in the analyses of hospital-
acquired and ICU-acquired episodes, with HL chi-squared P
values greater than 0.05 (0.74 and 0.15, respectively) and
AUC-ROC curve values of 0.80 in both groups.
We also evaluated model accuracy for the 1458 first severe
sepsis episodes in the training group (n = 1458 patients) ver-
sus all subsequent episodes (n = 258, including 56 after com-
munity-acquired severe sepsis, 96 after hospital-acquired
severe sepsis and 106 after ICU-acquired severe sepsis; Fig-
ure 1). AUC was 0.82 for first episodes and 0.82 for subse-
quent episodes. The difference was not significant according
to the Hanley and McNeil test [20]. Moreover, calibration was
satisfactory for both groups (HL chi squares P > 0.10).
Interestingly, model accuracy was similar for severe sepsis at
ICU admission (n = 586, AUC = 0.85) and later in the ICU stay
(days 2 to 4: n = 670, AUC = 0.82; days 5 to 7: n = 133, AUC
= 0.80; days 8 to 14: n = 200, AUC = 0.80; and days 15 to
28: n = 127, AUC = 0.80). Furthermore, multiple-site infection
was not associated with the rank of severe sepsis episode and
therefore did not correlate with the number of episodes (P =
0.87 by Fisher's exact test).
Performance was slightly lower in the validation cohort (Figure
3). The final model used on all episodes of severe sepsis
showed good calibration (HL chi-squared, 15.3, P = 0.06) and
good discrimination (AUC-ROC curve, 0.76). Results for com-
munity- and hospital-acquired infections were satisfactory,
with AUC-ROC curve values of 0.80 and 0.79, respectively,
and with HL chi-squares P values greater than 0.05 in both
groups (0.35 and 0.06, respectively). Prediction of early death
after ICU-acquired severe sepsis was less accurate, with an
AUC-ROC curve of 0.70 but an HL chi-squared P value of
0.02. These data are similar to those obtained from calibration
curves [See Additional Data File 1, Figure 1].
Chronic renal failure 29 (2.5) 15 (5.3) 0.01
Exactly one chronic illness 405 (34.4) 136 (48.4) < 10-4
Two or more chronic illnesses 94 (8.0) 42 (15.0) < 10-3
Diabetes mellitus 88 (7.5) 26 (9.3) 0.32
ICU stay (days) 11 (6 to 23) 8 (4 to 12) < 10-4
Hospital stay (days) 33 (19 to 57) 11 (6 to 17) < 10-4
Type of acquisition of first 
episode of severe sepsis
0.46
Community-acquired 471 (40) 102 (36.3)
Hospital-acquired 454 (38.7) 112 (39.9)
ICU-acquired 252 (21.4) 67 (23.8)
APACHE II = Acute Physiologic and Chronic Health Evaluation II; COPD = chronic obstructive pulmonary disease; ICU = intensive care unit; 
LOD = Logistic Organ Dysfunction; SAPS II = Simplified Acute Physiology Score II; SOFA = Sequential Organ Failure Assessment.
Table 1 (Continued)
Baseline characteristics at ICU admission of 1458 patients with severe sepsisAvailable online http://ccforum.com/content/13/3/R72
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Table 2
Baseline characteristics of the 1458 patients in the training cohort, on the first day of severe sepsis
Variables on the day with 
severe sepsis
Number of episodes of severe 
sepsis in patients alive 14 days after 
severe sepsis (n = 1367)
Number of episodes of severe sepsis 
in patients who died within 14 days 
after severe sepsis (n = 349)
P value Chi-squared test
Organ dysfunctions based on 
the LOD score
Neurological 386 (28.2) 155 (44.4) < 10-4
Cardiovascular 590 (43.2) 237 (67.9) < 10-4
Renal 1052 (77) 316 (90.5) < 10-4
Haematological 174 (12.7) 73 (20.9) < 10-4
Hepatic 199 (14.6) 98 (28.1) < 10-4
Procedures
Vasoactive and/or inotropic 
drugs
681 (49.8) 249 (71.3) < 10-4
Mechanical ventilation 943 (69) 299 (85.7) < 10-4
Arterial catheter 367 (26.8) 142 (40.7) < 10-4
Central catheter 769 (56.3) 266 (76.2) < 10-4
Swan catheter 70 (5.1) 48 (13.8) < 10-4
At least one intravascular 
catheter
817 (59.8) 278 (79.7) < 10-4
Urinary tract catheter 1081 (79.1) 311 (89.1) < 10-4
Treatments on the first day of 
severe sepsis
Corticosteroid 350 (25.6) 107 (30.7) 0.06
Antibiotic 1190 (87.1) 294 (84.2) 0.17
Extra-renal replacement 
therapy
68 (5) 51 (14.6) < 10-4
Early effective antibiotic 
therapy
1036 (75.8) 250 (71.6) 0.11
Microorganism
Escherichia coli 170 (12.4) 60 (17.2) 0.02
Streptococcus pneumoniae 104 (7.6) 22 (6.3) 0.41
Pseudomonas species 153 (11.2) 52 (14.9) 0.06
Staphylococcus aureus 173 (12.7) 44 (12.6) 0.98
Methicillin-resistant S. 
aureus
53 (3.9) 23 (6.6) 0.03
Methicillin-susceptible S. 
aureus
120 (8.8) 21 (6) 0.09
Candida species 42 (3.1) 20 (5.7) 0.02
Enterococcus species 124 (9.1) 41 (11.7) 0.13
Acinetobacter baumannii 14 (1) 3 (0.9) 0.78
Other Gram-positive 110 (8) 22 (6.3) 0.27
Multiple organisms 162 (11.9) 37 (10.6) 0.52
Resistant organisms 95 (6.9) 33 (9.5) 0.05
Unknown 581 (42.5) 124 (35.5) 0.02Critical Care    Vol 13 No 3    Adrie et al.
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We also evaluated model performance at different times of the
total study period. To this end, we considered three subperi-
ods: 1997 to 2000, 2001 to 2004, and after 2004. Results
were similar for these three periods in terms of discrimination
and calibration (AUC = 0.802, HL chi-squared = 10.8 for the
first period; 0.832 and 4.8 for the second period; and 0.832
and 11.0 for the final period).
Moreover, we compared our model with daily severity scores.
APACHE II, MPM II0 and SAPS II scores were significantly less
accurate than our model, with AUCs of 0.73, 0.66 and 0.72,
respectively (P value < 10-4 in all cases), and poor calibration
(HL chi-squared P values of 0.03, < 10-4 and 0.02, respec-
tively; Figure 4).
Discussion
We found that predicting death within 14 days after the onset
of severe sepsis during the first 28 days in the ICU was feasi-
ble in patients with no to three previous episodes of severe
sepsis. By adjusting for confounders, we were able to build a
predictive model in a training cohort that performed well in the
validation cohort. If used in randomised trials, this prognostic
model might help to include patients with similar disease
severity and to improve adjustment for confounders.
We chose to study short-term mortality, despite the current
trend among researchers to focus on long-term mortality [21-
23]. Most studies of sepsis used 28-day all-cause mortality as
the primary end-point. However, life-limiting disease is a com-
mon risk factor for sepsis and may cause death shortly after
successful treatment of the septic episode. Early morbidity
associated with sepsis is dominated by the side effects of life-
supporting interventions (e.g., mechanical ventilation, dialysis
and vasoactive agents), whereas delayed morbidity (e.g., neu-
romuscular weakness, cognitive dysfunction and neuropsychi-
atric sequelae) is chiefly related to prolonged ICU
management. Sepsis is an acute event and its main manifesta-
tion, acute organ dysfunction, does not seem to be associated
with long-term mortality in patients who survive the original
insults [23]. Furthermore, many studies failed to adjust appro-
priately for treatment-limitation decisions such as do not resus-
citate (DNR) given early (less than two days) or later during the
ICU stay. Underlying illness is the main reason for DNR orders,
which are taken in up to half the patients who die in the ICU
[24]. Moreover, treatment-limitation decisions were found to
be independently associated with ICU death [25].
Severe infections per se are associated with a decrease in life
expectancy. In a study that included controls from the general
population, sepsis not only caused acute mortality, but also
increased the risk of death for up to five years after the septic
episode, even after adjustment for pre-existing co-morbidities
[26]. The risk of delayed death during the first year was asso-
ciated with the severity of the septic episode [26]. Several
other studies showed that mortality and morbidity rates
remained increased for several years among hospital survivors
of infection and sepsis [27-31]. However, there is a two-way
relation between acute and chronic illnesses. Chronic disease
Site of infection
Pneumonia 668 (48.9) 171 (49) 0.96
Peritonitis 187 (13.7) 55 (15.8) 0.32
Urinary tract 186 (13.6) 52 (14.9) 0.53
Exacerbation of COPD 127 (9.3) 33 (9.5) 0.92
All forms of bacteraemia 425 (31.1) 134 (38.4) 0.01
Primary bacteraemia 129 (9.4) 34 (9.7) 0.86
Associated bacteraemia 296 (21.7) 100 (28.7) < 10-2
Catheter-related infection 86 (6.3) 22 (6.3) 0.99
Miscellaneous infection sites 136 (9.9) 39 (11.2) 0.50
Multiple infection sites 156 (11.4) 59 (16.9) < 10-2
Rank of severe sepsis 
episode
0.01
One 1177 (86.1) 281 (80.5)
Two 152 (11.1) 49 (14)
Three 30 (2.2) 17 (4.9)
Four 8 (0.6) 2 (0.6)
COPD = chronic obstructive pulmonary disease; LOD = Logistic Organ Dysfunction.
Table 2 (Continued)
Baseline characteristics of the 1458 patients in the training cohort, on the first day of severe sepsisAvailable online http://ccforum.com/content/13/3/R72
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increases the risk of infection and severe sepsis, and survivors
of severe sepsis may experience an increase in their burden of
chronic disease, which in turn may further elevate the risk for
subsequent acute illnesses, thereby initiating a spiral of events
that eventually causes death [23]. Therefore, a reasonable
hypothesis is that early mortality (e.g., within 14 days) can be
ascribed to the severity of acute severe sepsis [32,33] and to
the effectiveness of treatment, rather than to underlying
chronic illnesses, provided patients with treatment-limitation
decisions are excluded, as in our study. Short-term survival
may need to be viewed as a surrogate measure, because it is
desirable only when followed by long-term survival with an
acceptable quality of life. On the other hand, focusing on very
long-term mortality, which is extremely relevant to healthcare-
cost issues, may mask beneficial effects of drugs used to treat
sepsis if the patient dies later on as a result of an underlying
chronic illness associated with a risk of sepsis [23]. High
death rates due to underlying diseases may explain why many
therapeutic trials in patients with severe sepsis failed to detect
benefits related to the experimental treatments. Although
emphasis is often put on the α risk of false-positive results, the
β risk of missing true effects as a result of inadequate statisti-
cal power is just as important for the overall population,
because false-negative results deprive patients of effective
treatments. Therefore, when designing large trials of treat-
ments for severe sepsis, it may be appropriate to select candi-
date treatments in preliminary trials that use short-term
mortality as the primary endpoint.
We found that mortality from severe sepsis could be predicted
based on variables associated with the PIRO concept [34] (P:
co-morbidities, McCabe; I: multiple-site infection, number of
severe sepsis episodes; and R and O: organ dysfunction and
vasoactive drug use). These findings are in accordance with a
recent report of a PIRO-based score designed to predict 28-
day mortality from sepsis, thus focusing on a nearer time hori-
zon than many recent studies evaluating longer term outcome
(e.g., longer than three months) [21]. Studies of pneumonia
already used 14-day mortality as the primary outcome of inter-
est, to separate the impact of pneumonia from that of co-mor-
bidities or other factors [32,33].
Our study has several limitations. First, the location of the
patient before hospital admission was not recorded in the early
Table 3
Generalised linear model obtained in our study
Main effect Beta estimate Odds ratio
95% CI
P value
Intercept -4.9419 - < 10-4
Parameters on the day of severe sepsis
LOD (per point) 0.1951 1.22 (1.16 to 1.27) < 10-4
Septic shock 0.3335 1.40 (1.08 to 1.81) 0.01
First episode of severe sepsis - - -
Second episode of severe sepsis 0.2304 1.26 (0.96 to 1.66) 0.10
Third or fourth episode of severe sepsis 0.9719 2.64 (1.71 to 4.08) < 10-4
Multiple sites of infection 0.3734 1.45 (1.04 to 2.03) 0.03
Variables at ICU admission
SAPS (per point) 0.0244 1.02 (1.01 to 1.03) < 10-4
Fatal illness by McCabe Score(score 2 or 3) 0.6749 1.96 (1.43 to 2.70) < 10-4
No chronic illness - - -
Exactly one chronic illness 0.5592 1.75 (1.25 to 2.45) 0.001
Two or more chronic illnesses 0.8084 2.24 (1.39 to 3.62) 0.001
The area under the Receiver-Operating Characteristics curve was 0.822 and the Hosmer-Lemeshow chi-squared test was 8.6 (P > 0.05, 8 df), 
indicating good discrimination and good calibration of the final model in the training cohort. The following variables were tested in the generalized 
linear model: Logistic Organ Dysfunction (LOD), Sequential Organ Failure Assessment (SOFA), septic shock, high-dose vasoactive drugs 
(epinephrine and/or norepinephrine > 0.1 γ/kg/min), multiple sites of infection, Simplified Acute Physiology Score (SAPS) II, age, number of 
chronic organ failures (none, exactly one or two or more), arterial, central venous line or Swan-Ganz catheter, diagnosis at intensive care unit (ICU) 
admission, year of admission, centre, early effective antibiotic therapy, corticosteroid therapy, male gender, main symptom (multiple organ failure 
and cardiogenic shock), metastatic cancer, mechanical ventilation, urinary tract catheter, sedation, extrarenal replacement therapy, McCabe score, 
nature of the microorganism (E. coli, Candida species and methicillin-susceptible S. aureus), infection site and LOD increase from the day before 
to the day of severe sepsis diagnosis.
To calculate the predicted risk of death for each patient:
- compute the logit: logit = sum ('Beta estimate' multiplied by value of corresponding parameter)
- compute the probability, using the logit: P = (exp (logit)) divided by (1+exp(logit))Critical Care    Vol 13 No 3    Adrie et al.
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Figure 2
Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) chi-squared test results of the prediction model in the training  cohort Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) chi-squared test results of the prediction model in the training 
cohort. n = 1458 patients, 1716 episodes, according to the type of severe sepsis (community-, hospital- or ICU-acquired). Dashed curves represent 
95% confidence intervals (CI) of the area under the curve (AUC) of the ROC curve.Available online http://ccforum.com/content/13/3/R72
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Figure 3
Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) chi-square test results of the prediction model in the validation  cohort Receiver-Operating Characteristics (ROC) curves and Hosmer-Lemeshow (HL) chi-square test results of the prediction model in the validation 
cohort. n = 810, 1021 episodes, according to the day of severe sepsis. Dashed curves represent 95% confidence intervals (CI) of the area under 
the curve (AUC) of the ROC curve.Critical Care    Vol 13 No 3    Adrie et al.
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years of our database. Patients who are chronically in contact
with healthcare systems on an outpatient or day-hospital basis
(e.g., for chronic dialysis or other chronic treatments) are at
risk for severe infection with resistant strains, although they are
not admitted [35]. We have been recording this variable since
April 2000 and have found that fewer than 5% of patients
directly admitted to the ICUs included in the database are
recipients of chronic hospital-based outpatient care. Moreo-
ver, hospital-acquired infection (in patients transferred to the
ICU from other wards) was diagnosed in more than half our
patients and was not associated with 14-day mortality (Table
1, P = 0.85). Second, calibration as assessed using the HL
goodness-of-fit was unsatisfactory (HL chi-squared P < 0.05),
although discrimination remained good (AUC-ROC = 0.7,
95% CI 0.65 to 0.75) for ICU-acquired severe sepsis in the
validation dataset (Figure 3). Third, our model was developed
in a single type of healthcare system. External validation stud-
ies are needed before the model can be used in countries that
have different healthcare systems from the one in France.
Finally, it should be borne in mind that the relevance of 14-day
mortality to long-term treatment benefits remains to be evalu-
ated. However, our model was clearly superior to widely used
models (Figure 4) and may prove helpful for designing and
analysing future trials.
Conclusions
We developed a model for predicting death within 14 days
after the diagnosis of the first, second, third or fourth episode
of severe sepsis occurring within 28 days after ICU admission.
The model is based on a few readily available variables. It may
help to evaluate the effectiveness of new drugs or treatment
strategies in reversing severe sepsis. In contrast, long-term
mortality may be a better marker for the efficacy of treatments
directed against sepsis, because recovery from sepsis may be
followed by death due to underlying illnesses.
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Key messages
￿  We developed a model for predicting short-term (14 
days) mortality after each episode of severe sepsis, 
using readily available variables. The model proved very 
accurate for predicting mortality after one to four severe 
sepsis episodes in the ICU.
￿  The model was accurate for community-, hospital- and 
ICU-acquired episodes of severe sepsis, in both the 
training and validation cohort (n = 2737 episodes over-
all).
￿  This prediction model is designed to predict death 
directly related to severe sepsis, as opposed to co-mor-
bidities or DNR decisions, which contribute substan-
tially to longer-term mortality rates.
￿  Our model may help to evaluate the effectiveness of a 
drug or strategy in severe sepsis, by avoiding type II 
errors stemming from inadequate statistical power to 
detect therapeutic effects despite the substantial mor-
tality due to co-morbidities, treatment-limitation deci-
sions and DNR orders.
￿  In future studies, our model may help to select uniform 
patient groups for inclusion in clinical trials and to 
improve adjustment for confounders.
Figure 4
Comparison of our prediction model with other, widely used models Comparison of our prediction model with other, widely used models. 
The final study model (blue line) used on all episodes of severe sepsis 
showed good calibration (Hosmer-Lemeshow (HL) chi-squared 15.3, P 
= 0.06) and good discrimination (area under the curve (AUC)- receiver-
operating characteristics (ROC) curve, 0.76). Acute Physiologic and 
Chronic Health Evaluation (APACHE) II, Mortality Probability models II0 
(MPM0 II) and Simplified Acute Physiology Score (SAPS) II scores 
were significantly less accurate than our model, with AUCs of 0.73, 
0.66 and 0.72, respectively (P value < 10-4 in all cases), and poor cali-
bration (HL chi-squared P values of 0.03, < 10-4 and 0.02, respec-
tively).Available online http://ccforum.com/content/13/3/R72
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